Kadmon Corporation - Company & Market Research Reports

Kadmon is a fully integrated biopharmaceutical company that focuses on small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Its lead product candidates is KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases. The company is headquartered in New York.

From
From
From
From
From
From
Psoriasis - Pipeline Review, H2 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 726 Pages
From
Type 2 Diabetes - Pipeline Review, H1 2018 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1109 Pages
From
From
Psoriasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 709 Pages
From
Type 2 Diabetes - Pipeline Review, H2 2017 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H2 2017

  • Drug Pipelines
  • 1126 Pages
From
NASH Drugs Market, 2015 - 2025 - Product Thumbnail Image

NASH Drugs Market, 2015 - 2025

  • Report
  • 188 Pages
From
From
From
Rheumatoid Arthritis - Pipeline Review, H2 2017 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2017

  • Drug Pipelines
  • 1051 Pages
From
Rheumatoid Arthritis - Pipeline Review, H1 2017 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H1 2017

  • Drug Pipelines
  • 1020 Pages
From
From
Loading Indicator
adroll